Biohaven (BHVN) Soars 25% on FDA Drug Review, Price Target Upgrade

Biohaven Ltd (NYSE:BHVN) soared up to 25.02 percent on Thursday, closing at $14.69 apiece, as investors gobbled up shares after its drug candidate for spinocerebellar ataxia (SCA) moved closer to commercialization. This followed a regulatory filing on the same day the Food and Drug Administration (FDA) officially accepted for review the listed firm’s resubmitted new […]